IRCT20201202049568N1招募中1 期
The safety and efficiency evaluation of allogenic Natural Killer cell therapy in relapsed Neuroblastoma pediatric patients post hematopoietic stem cell transplantation: Phase I clinical study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 year 至 15 years（—）
- 性别
- All
入选标准
- •Any amount of neuroblastoma tumor cells in the bone marrow that can be seen from at least one aspiration sample
- •Tumors seen on CT in at least one soft tissue.
- •Have at least 1 MIBG- lesion with a score of 1-2 Curie
- •The patient has a life expectancy of at least 12 weeks.
- •The function of the patients organs must be acceptable.
- •Patient age from 1 to 15 years
排除标准
- •Active or uncontrollable infection
- •History of allergies or any hypersensitivity to animal proteins
- •Heart failure
- •Serious mental and physical disabilities
- •Participation in any other clinical trial
研究者
相似试验
招募中
1 期
Application of Cord Blood Platelet Gel (CBPG) for the treatment of non-healing skin ulcers due to the cutaneous chronic GVHDIRCT20190101042197N1Royan Stem cell Technology Co.15
已完成
1 期
A phase I/IIa safety and efficacy study of allogeneic periodontal ligament-derived mesenchymal stromal cell sheet product (TWP-0001) in patients with periodontitis, consisting of 1 wall intrabony defect, Class III furcation defect, or horizontal defect, with probing depths of 4 - 9 mm after the initial therapyJPRN-UMIN000034310Tokyo Medical and Dental University6
已完成
1 期
Periodontal regeneration by allogeneic periodontal ligament-derived mesenchymal stromal cell sheetsPeriodontitis, consisting of 1 wall intrabony defect, Class III furcation defect, or horizontal defect, with probing depths of 4-9mm after the initial therapyJPRN-jRCT2090220391Tokyo women's medical university, institute of advanced biomedical engineering and science, and department of oral and maxillofacial surgery, Takanori Iwata6
已完成
1 期
Evaluation of the safety and efficacy of allogenic hematopoietic stem cell transplantation (HSCT) from HLA-mismatched related donors using alemtuzumab in patients with hematological malignancies.Hematological malignanciesJPRN-C000000357GCP-ISS HE0402 group48
招募中
1 期
Effect of NK cell therapy in COVID-19IRCT20200417047113N1Middle East Gene Therapy corporation70